Follicular development in a 7-day versus 4-day hormone-free interval with an oral contraceptive containing 20 mcg ethinyl estradiol and 1 mg norethindrone acetate-Reference-Cited by-同舟云学术

Follicular development in a 7-day versus 4-day hormone-free interval with an oral contraceptive containing 20 mcg ethinyl estradiol and 1 mg norethindrone acetate

Published:2009-03 Issue:3 Volume:79 Page:182-188
ISSN:0010-7824
Container-title:Contraception
language:en
Short-container-title:Contraception

Author:

Rible Radhika D.,Taylor DeShawn,Wilson Melissa L.,Stanczyk Frank Z.,Mishell Daniel R.

Publisher

Elsevier BV

Subject

Obstetrics and Gynaecology,Reproductive Medicine

Reference29 articles.

1. Activity of the pituitary–ovarian axis in the pill-free interval during use of low-dose combined oral contraceptives;Van Heusden;Contraception,1999

2. A multicenter, uncontrolled clinical investigation of the contraceptive efficacy, cycle control, and safety of a new low-dose oral contraceptive containing 20 μg ethinyl estradiol and 100 μg levonorgestrel over six treatment cycles;Bannemerschult;Contraception,1997

3. Large observational trial of a new low-dose oral contraceptive containing 20 μg ethinylestradiol and 100 μg levonorgestrel (Miranova®) in Germany;Hite;Eur J Contracep Reprod Health Care,1999

4. Ovulatory potential of preovulatory sized follicles during oral contraceptive treatment;Elomaa;Contraception,1999

5. The effect of extending the pill-free interval on follicular activity: triphasic norgestimate/35 mcg ethinyl estradiol versus monophasic levonorgestrel/20 mcg ethinyl estradiol;Creinin;Contraception,2002

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. U.S. Selected Practice Recommendations for Contraceptive Use, 2024;MMWR. Recommendations and Reports;2024-08-08

2. Patterns of endogenous and exogenous ovarian hormone modulation on recovery metrics across the menstrual cycle;BMJ Open Sport & Exercise Medicine;2021-07

3. Use of Model-Informed Drug Development to Streamline Development of Long-Acting Products: Can These Successes Be Translated to Long-Acting Hormonal Contraceptives?;Annual Review of Pharmacology and Toxicology;2021-01-06

4. FSRH Guideline (January 2019, amended November 2020) Combined Hormonal Contraception;BMJ Sexual & Reproductive Health;2019-01

5. Systematic Review of Ovarian Activity and Potential for Embryo Formation and Loss during the Use of Hormonal Contraception;The Linacre Quarterly;2018-11